Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction on Monday, January 1st. The shares were sold at an average price of $3.69, for a total transaction of $73,800.00. Following the transaction, the chief operating officer now directly owns 948,356 shares of the company’s stock, valued at approximately $3,499,433.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Arrowhead Pharmaceuticals Inc (ARWR) traded up $0.92 during midday trading on Wednesday, reaching $4.64. 5,880,000 shares of the company were exchanged, compared to its average volume of 1,260,000. Arrowhead Pharmaceuticals Inc has a fifty-two week low of $1.42 and a fifty-two week high of $4.88. The company has a market capitalization of $347.20, a P/E ratio of -9.87 and a beta of 1.79. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.63 and a quick ratio of 3.63.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its stake in Arrowhead Pharmaceuticals by 252.2% during the third quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock worth $192,000 after buying an additional 31,765 shares during the last quarter. Virtu KCG Holdings LLC raised its stake in Arrowhead Pharmaceuticals by 115.6% during the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after buying an additional 53,215 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in Arrowhead Pharmaceuticals by 10.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock worth $742,000 after buying an additional 16,103 shares during the last quarter. Allianz Asset Management GmbH bought a new position in Arrowhead Pharmaceuticals during the third quarter worth $1,958,000. Finally, Geode Capital Management LLC raised its stake in Arrowhead Pharmaceuticals by 3.4% during the first quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock worth $1,226,000 after buying an additional 21,654 shares during the last quarter. 20.05% of the stock is owned by institutional investors and hedge funds.
WARNING: “Insider Selling: Arrowhead Pharmaceuticals Inc (ARWR) COO Sells 20,000 Shares of Stock” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/03/insider-selling-arrowhead-pharmaceuticals-inc-arwr-coo-sells-20000-shares-of-stock.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.